Experience with hormone receptors in renal cancer
- PMID: 1965539
- DOI: 10.1007/BF02549737
Experience with hormone receptors in renal cancer
Abstract
The hormone receptor concentrations in tumour tissues from 20 renal carcinoma patients were determined before postoperative medroxyprogesterone acetate (MPA) therapy was started. Except for glucocorticoid receptors, the concentrations were either not measurable or were extremely low. The question is whether MPA therapy, solely on the strength of its character as a general roborant, is still useful in the treatment of renal tumours, even when it fails to exercise primary influence because of the absence of suitable receptors. None of the 20 patients was treated with MPA.
Similar articles
-
Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study.J Urol. 1987 Dec;138(6):1379-81. doi: 10.1016/s0022-5347(17)43647-0. J Urol. 1987. PMID: 2824861 Clinical Trial.
-
Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.Scand J Urol Nephrol Suppl. 1988;110:185-7. Scand J Urol Nephrol Suppl. 1988. PMID: 2973122 No abstract available.
-
Re: Deoxyribonucleic acid content and medroxyprogesterone acetate treatment in metastatic renal cell carcinoma.J Urol. 1990 Sep;144(3):749-50. doi: 10.1016/s0022-5347(17)39577-0. J Urol. 1990. PMID: 2143789 No abstract available.
-
The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.Cancer Treat Rev. 1988 Sep;15(3):195-209. doi: 10.1016/0305-7372(88)90003-5. Cancer Treat Rev. 1988. PMID: 2974757 Review. No abstract available.
-
An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.Chemioterapia. 1986 Jun;5(3):164-72. Chemioterapia. 1986. PMID: 2941173 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical